Elisabeth Parker

Elisabeth Parker

Company: Macrophage Pharma

Job title: Director of Business Development


Elisabeth has 20 years’ experience of R&D and commercialisation of translational research through licensing and spin-outs.

Prior to joining Macrophage Pharma, Elisabeth worked for Cancer Research Technology Ltd (CRT), the development and commercialisation arm of Cancer Research UK, and served as a non-executive Director of Arquer Ltd and Azeria Therapeutics Ltd.  Prior to joining CRT, Elisabeth was Head of Research at KS Biomedix, a UK quoted Biopharmaceutical company. Elisabeth holds a PhD from the Medical Faculty, Lund University, Sweden.


Regulating Macrophage Polarization to Create a Tumor Suppressive Environment 2:30 pm

• Discuss macrophage phenotypes, the tumour microenvironment and implications for immune response and prognosis • Review Esterase Sensitive MotifTM drugs to control polarity and lock specific phenotypes • Explore potential targets and immuno-oncology combinationsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.